Chengquan Shen1, Jing Liu2, Jirong Wang1, Xiulong Zhong1, Dahai Dong1, Xiaokun Yang3, Yonghua Wang4. 1. Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China. 2. Department of Research Management and International Cooperation, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China. 3. Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China. Electronic address: doctorxiaokun@sina.com. 4. Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China. Electronic address: doctoryonghua123@sina.com.
Abstract
BACKGROUND: Recent studies have demonstrated that immune-associated genes (IAGs) play an important role in the occurrence and progression of clear renal clear cell carcinoma (ccRCC). Novel biomarkers and a reliable prognostic prediction model for ccRCC patients are still limited. The objective of this study was to develop a IAGs signature and validate its prognostic value in ccRCC using bioinformatic methods and publicly database. METHODS: In the present study, we identified differentially expressed IAGs in ccRCC based on The Cancer Genome Atlas (TCGA) database. A prognostic IAGs risk model was further developed and its prognostic and predictive value was evaluated by survival analysis and nomogram. RESULTS: A total of 681 differentially expressed IAGs were identified and seven IAGs (IFI30, WNT5A, IRF9, AGER, PLAUR, TEK, BID) were finally selected in a IAGs signature. Survival analysis revealed that high IAGs risk scores were significantly related to poor survival outcomes. The IAGs signature was demonstrated as an independent prognostic factor and closely related to the metastasis status of ccRCC. A nomogram with clinicopathologic characteristics and IAGs signature was also constructed to superiorly predict prognosis of ccRCC patients. CONCLUSIONS: We identified seven IAGs as a potential signature for reflecting the prognosis of ccRCC based on TCGA database. Further clinical trials are needed to validate our observations and the mechanisms underlying the prognostic value of IAGs signature in ccRCC also deserve further experimental exploration.
BACKGROUND: Recent studies have demonstrated that immune-associated genes (IAGs) play an important role in the occurrence and progression of clear renal clear cell carcinoma (ccRCC). Novel biomarkers and a reliable prognostic prediction model for ccRCCpatients are still limited. The objective of this study was to develop a IAGs signature and validate its prognostic value in ccRCC using bioinformatic methods and publicly database. METHODS: In the present study, we identified differentially expressed IAGs in ccRCC based on The Cancer Genome Atlas (TCGA) database. A prognostic IAGs risk model was further developed and its prognostic and predictive value was evaluated by survival analysis and nomogram. RESULTS: A total of 681 differentially expressed IAGs were identified and seven IAGs (IFI30, WNT5A, IRF9, AGER, PLAUR, TEK, BID) were finally selected in a IAGs signature. Survival analysis revealed that high IAGs risk scores were significantly related to poor survival outcomes. The IAGs signature was demonstrated as an independent prognostic factor and closely related to the metastasis status of ccRCC. A nomogram with clinicopathologic characteristics and IAGs signature was also constructed to superiorly predict prognosis of ccRCCpatients. CONCLUSIONS: We identified seven IAGs as a potential signature for reflecting the prognosis of ccRCC based on TCGA database. Further clinical trials are needed to validate our observations and the mechanisms underlying the prognostic value of IAGs signature in ccRCC also deserve further experimental exploration.